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Abstract. Hypertrophic cardiomyopathy (HCM) is mainly 
associated with myosin, heavy chain 7 (MYH7) and myosin 
binding protein C, cardiac (MYBPC3) mutations. In order to 
better explain the clinical and genetic heterogeneity in HCM 
patients, in this study, we implemented a target-next genera-
tion sequencing (NGS) assay. An Ion AmpliSeq™ Custom 
Panel for the enrichment of 19 genes, of which 9 of these did 
not encode thick/intermediate and thin myofilament (TTm) 
proteins and, among them, 3 responsible of HCM phenocopy, 
was created. Ninety-two DNA samples were analyzed by the 
Ion Personal Genome Machine: 73 DNA samples (training 
set), previously genotyped in some of the genes by Sanger 
sequencing, were used to optimize the NGS strategy, whereas 
19 DNA samples (discovery set) allowed the evaluation of NGS 
performance. In the training set, we identified 72 out of 73 
expected mutations and 15 additional mutations: the molecular 
diagnosis was achieved in one patient with a previously wild-
type status and the pre-excitation syndrome was explained in 
another. In the discovery set, we identified 20 mutations, 5 of 
which were in genes encoding non-TTm proteins, increasing 
the diagnostic yield by approximately 20%: a single mutation 
in genes encoding non-TTm proteins was identified in 2 out of 
3 borderline HCM patients, whereas co-occuring mutations in 
genes encoding TTm and galactosidase alpha (GLA) altered 
proteins were characterized in a male with HCM and multiorgan 
dysfunction. Our combined targeted NGS-Sanger sequencing-
based strategy allowed the molecular diagnosis of HCM 
with greater efficiency than using the conventional (Sanger) 
sequencing alone. Mutant alleles encoding non-TTm proteins 
may aid in the complete understanding of the genetic and 
phenotypic heterogeneity of HCM: co-occuring mutations of 
genes encoding TTm and non-TTm proteins could explain the 
wide variability of the HCM phenotype, whereas mutations in 
genes encoding only the non-TTm proteins are identifiable in 
patients with a milder HCM status.
Introduction
Hypertrophic cardiomyopathy (HCM), classically defined as the 
presence of idiopathic left ventricular hypertrophy, is the most 
common heritable cardiovascular disease (affecting at least 
1 in 500 individuals); it is typically transmitted in an autosomal 
dominant pattern (1-3); however, sporadic cases associated with 
de novo mutations (1,4) and patients with maternally-inherited 
HCM (5,6) have also been reported. HCM is recognized as an 
important cause of sudden cardiac death (SCD), heart failure 
and embolic stroke secondary to atrial fibrillation (2).
At present, Online Mendelian Inherithance in Man (OMIM) 
classifies 25 different HCM phenotypes (http://omim.
org/phenotypicSeries/PS192600) that are associated with as 
many different mutant genes, mostly encoding thick/interme-
diate and thin myofilament (TTm) proteins of the sarcomere. 
Disease-causing mutations in myosin, heavy chain 7 (MYH7) 
and myosin binding protein C, cardiac (MYBPC3) genes, 
encoding myofilament proteins, represent approximately 70% of 
>1,400 pathogenic alleles that have been characterized in HCM 
patients by using Sanger sequencing (2). Pathogenic alleles 
that do not encode for TTm proteins have also been identified 
in some HCM patients (7-12). Mutations in the genes, galacto-
sidase alpha (GLA), lysosome-associated membrane protein 2 
(LAMP2), and protein kinase AMP-activated non-catalytic 
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subunit gamma 2 (PRKAG2), are responsible for distinct meta-
bolic storage disorders with a clinical presentation and pattern 
of left-ventricular hypertrophy similar to HCM (1,3,13).
However, pathogenic alleles are not identified in 28-40% of 
HCM patients with a family history of HCM and 50-90% of 
sporadic HCM cases (13,14). On the other hand, 5-10% of HCM 
patients carry more than one mutation affecting one or more 
different genes (15); these complex genotypes are usually iden-
tified in patients with severe left ventricular hypertrophy (16), 
or with end-stage HCM (17) and in patients with severe 
manifestations of the disease, including advanced heart failure 
symptoms and sudden death (1,14).
In addition, the broad genetic and allelic heterogeneity 
can also be associated with a highly variable clinical pheno-
type, ranging from asymptomatic forms to sudden cardiac 
death (1,13), even within the same family and amongst family 
members that share the same pathogenic allele (18,19).
The conventional Sanger sequencing of single amplicons 
of sarcomeric genes is labor intensive, time consuming and 
expensive, showing in a large number of patients a negative test 
or a positive test, but associated with a low predictive clinical 
outcome. In consideration of these limitations, it is reason-
able to adopt the massively parallel sequencing ability of the 
Next Generation Sequencing (NGS) technologies to decrease 
run times, lower the costs, use smaller amounts of genomic 
DNA (20) and, analyzing a larger number of genes, better 
decipher the relationship between genetic and phenotypic 
heterogeneity (21,22). In this context, the NGS methodology 
is replacing the conventional technology, in particular for the 
diagnosis of genetic disorders with high genetic heterogeneity 
that involve the screening of several genes or few genes with 
large coding region (23,24).
In this study, we used the NGS methodology, applied to 
the molecular characterization of HCM patients, to determine 
whether the screening of additional genes encoding non-TTm 
proteins may contribute to the better clarification of the rela-
tionship between the phenotypic and genotypic heterogeneity 
of HCM.
Patients and methods
Patients. All patients [n=92; mean age, 44.5 (±18.7) years; 
age range, 2-78 years] gave their informed consent to the 
study that was conducted according to the Declaration of 
Helsinki. The subjects were recruited between 2007 and 2015 
from Italian Cardiology Units and addressed to our Human 
Genetics Laboratory for molecular diagnosis of HCM. The 
clinical diagnosis of primary HCM was based on medical 
history, a physical examination and on the echocardiographic 
demonstration of a hypertrophied left ventricle (LV) that could 
not be explained by another cardiac or systemic disease. In 
adults, a maximal LV wall thickness (LVWT) ≥15 mm, or the 
equivalent relative to the body surface area in children, was 
considered the determining criterion for HCM; the maximal 
LVWT between 10 and 14 mm, in conjunction with other 
features (i.e., family history, electrocardiogram abnormalities) 
prompted the diagnosis of borderline HCM (25,26).
The phenocopy of HCM was suspected in the presence of 
multiorgan involvement. In these cases, a multidisciplinary 
clinical approach was adopted for the final diagnosis (27).
The genomic DNA of each patient was extracted from 
peripheral leukocytes, using QIAsymphony S (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. 
Among the 92 DNA samples, 73 were used as a training set 
to optimize the performance of NGS technology; these DNA 
samples were already genotyped by the Sanger sequencing of 
6 genes encoding TTm proteins [MYH7, MYBPC3, troponin T2, 
cardiac type (TNNT2), actin, alpha, cardiac muscle 1 (ACTC1), 
tropomyosin 1 (alpha) (TPM1) and troponin I3, cardiac 
type (TNNI3)] (1,3) and, where appropriate, another 2 genes 
encoding myofilament proteins [myosin light chain (MYL)2 
and MYL3] (1,3), or 3 genes (GLA, LAMP2 and PRKAG2) 
responsible for rare metabolic disorders (1,3,13), were analyzed. 
This series has 63 DNA samples with mutant genotypes and 
10 DNA samples with no previously identified mutations.
Another group of 19 DNA samples was adopted as the 
discovery set to evaluate the performance of NGS methodology 
in clinical routine HCM testing.
The clinical parameters (age at onset of HCM, LVWT, 
automatic implantable cardioverter defibrillator, family history 
of HCM/sudden cardiac death, left ventricular ejection fraction 
and other medical issues) were carefully reviewed for patients 
belonging at the discovery set and for those of the training 
set that, after NGS analysis, showed additional mutations in 
genes originally not analyzed by Sanger sequencing. Among 
these patients, of which 14 were males and 12 were female, the 
mean age at onset was 33.6 (±19.0) years, with an age range of 
1-72 years; the mean LVWT was 18.7 (±6.6) mm and ranged 
from 10 to 34 mm; the mean LVEF (%) was 59.8 (±10.4).
Gene panel design. To implement the diagnostic genetic testing 
for HCM patients using NGS technology, in addition to the 
11 genes previously screened, after analyzing the literature, we 
included additional 8 genes deemed most plausibly involved in 
the HCM phenotype. Among these, 2 genes encode myofila-
ment proteins [thin: troponin C1, slows skeletal and cardiac 
type (TNNC1); and thick: myosin, heavy chain 6 (MYH6)]; one 
encodes a protein located in the M-band [myomesin 1 (MYOM
1)] (7); two encode Z-disk constituents [myozenin 2 (MYOZ2) 
and ankyrin repeat domain 1 (ANKRD1)] (8,9); vinculin (VCL) 
encodes the main costameric protein (10), calretic-
ulin 3 (CALR3) encodes a Ca2+ sensitive/handling protein (11) 
and caveolin 3 (CAV3) encodes the major membrane protein of 
caveolae (12).
An Ion AmpliSeq™ Custom Panel (IACP) for the muta-
tion screening of these 19 genes was designed using the 
Ion AmpliSeq Designer (IAD) software v.2.0.3. The design 
included all the coding exons with additional 10 bp of adjacent 
intronic regions. Overall, it represented approximately 42 kb 
of the target DNA sequence, i.e., 284 exons and 452 amplicons 
divided into 2 pools of primers for multiplex PCR.
Library preparation and NGS. DNA libraries were prepared 
using the Ion Ampliseq™ Library kit 2.0 (Thermo Fisher 
Scientific, Carlsbad, CA, USA) following the manufacturer's 
instructions. 
Briefly, following quantification with a NanoDrop spec-
trophotometer (Thermo Fisher Scientific), 10 ng of genomic 
DNA was used in the multiplex PCR amplification of each of 
the 2 primer pools. For each sample, the 2 sets of multiplexed 
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amplicons were subjected to following steps: partial diges-
tion of the primers and amplicon phosphorylation with FuPa 
reagent (Thermo Fisher Scientific), ligation of the barcode 
adapters and purification by Agencourt® AMPure® XP 
Reagent (Beckman Coulter, Brea, CA, USA).
All the DNA libraries were quantified by the Agilent 
High Sensitivity DNA kit on a 2100 Bioanalyzer (Agilent 
Technologies, Milan, Italy) and a Qubit® 2.0 Fluorometer 
using the dsDNA High Sensitivity assay kit (Thermo Fisher 
Scientific) before being diluted to a final concentration of 
100 pmol/l in low TE; subsequently, 3 µl of each sample were 
pooled to a final concentration of 100 pmol/l. The final pool 
was further diluted to a concentration of 12 pmol/l in water 
and subjected to emulsion PCR and enrichment of Ion Sphere 
Particles (ISPs) using the Ion Torrent OneTouch™ 2 system 
(Thermo Fisher Scientific) according to the manufacturer's 
instructions; confirmation of template-positive ISPs and valida-
tion of enrichment were performed on Qubit® 2.0 Fluorometer 
using Ion sphere quality control kit (Thermo Fisher Scientific), 
according to the manufacturer's protocol. Enriched ISPs were 
loaded on Ion 314 or 316 chips and sequenced on the Ion Torrent 
Personal Genome Machine (PGM) (both from Thermo Fisher 
Scientific); the sequencing was performed using the PGM 200 
Sequencing kit (Thermo Fisher Scientific).
Bioinformatics analysis. Raw data from PGM sequencing runs 
were processed using 2 software pipelines, Ion Reporter 4.0 
(Thermo Fisher Scientific) and the CLC Genomics Workbench 
software version 6.5 (CLC Bio, Aarhus, Denmark). Sequencing 
reads were filtered for low-quality reads, trimmed for adapter 
sequences and tagged as belonging to the specific patient 
according to the barcode.
Using the spectrum of the expected mutations in the 
training set, the parameters for variant calling were established 
to minimize the number of false-positive results and guarantee 
the characterization of all the true-positive calls; the following 
filter thresholds were considered: minimum allele frequency for 
single-nucleotide polymorphism (SNP) and indel (SNP% ≥20), 
phred-like quality score of the called variant (Qcall ≥20) and 
depth of coverage (Depth ≥20).
Coverage assessment was carried out by the Ion Coverage 
Analysis plug-in v4.0-r77897 and CLC Bio Coverage statistics 
module. Moreover, alignments were visually inspected with 
Integrative Genome Viewer (28) to know the depth of analysis 
of each single nucleotide of the target region and the infor-
mation concerning the read of the fragments with forward or 
reverse primer only.
We considered correctly covered, and hence suitable for 
mutations analysis, only exons (and their adjacent boundary 
sequences) with a read depth >20 reads (20X) for each targeted 
nucleotide; in detail, this parameter of coverage was requested 
for i) the 99% of the target region with respect to 11 genes 
previously screened in routine molecular diagnosis by Sanger 
sequencing; ii) the 95% of the target region for the remaining 
8 genes.
Filtering approach and putative mutations assignment. 
To distinguish potential disease-causing mutations from 
common variants with a minor allele frequency (MAF) ≥1%, 
the nucleotide alterations were initially filtered against the 
variations reported in dbSNP138 (http://www.ncbi.nlm.nih.
gov/SNP/), the HapMap v3.3, the Exome Variant Server 
(EVS; http://evs.gs.washington.edu/EVS/), the 1000 Genomes 
Project (www.1000genomes.org) hg19 (patch9) and the Exome 
Aggregation Consortium (ExAC; exac.broadinstitute.org).
Nonsense, frameshift, canonical splice site (±2 bp) muta-
tions, together with missense mutations already unequivocally 
described as associated with the HCM phenotype (or with 
other forms of cardiomyopathies), and reported in the Human 
Genome Mutation Database (29) (HGMD, http://www.hgmd.
org/; release 2015.4) as disease-causing mutations (DM), were 
considered as ‘pathogenic variants’.
To evaluate the effect on protein function of the missense 
mutations not described in the literature or annotated in 
HGMD as DM? (DM of questionable pathological relevance), 
the in silico prediction of pathogenicity was established by 
Polyphen2 (http://genetics.bwh.harvard.edu/pph2/), Mutation 
Taster (http://www.mutationtaster.org/) and SIFT human 
protein (http://sift.jcvi.org/) algorithms. Afterward, we classi-
fied these missense mutations either as ‘pathogenic variants’ 
when the pathogenic impact was predicted by all algorithms or 
as ‘likely pathogenic variants’ when the pathogenic impact was 
predicted by 2 out of 3 algorithms.
Taking into account the stringent above-mentioned criteria, 
we evaluated that, in the training set, 67 out of 73 expected 
mutations were classifiable as ‘pathogenic variants’, while the 
remaining 6 were predicted as ‘likely pathogenic variants’; of 
these, 52 mutations were annotated in HGMD.
Sanger sequencing of uncovered regions and validations of 
putative variants. Using Sanger sequencing, we analyzed the 
exons classified as uncovered in order to reach the percentage of 
target region correctly covered; moreover, the new non-synon-
ymous nucleotide variants identified were also confirmed by 
Sanger sequencing.
In brief, exons containing the nucleotide variants were 
amplified using Taq Platinum (Invitrogen, Carlsbad, CA, 
USA) with specific flanking primers and sequenced using 
Big Dye v3.1 (Thermo Fisher Scientific); fragments of PCR 
and products of sequencing were purified by Agencourt 
AMPure XP and CleanSEQ, respectively, on automated station 
Biomek FX (Beckman Coulter). Sequencing was carried out 
on 3130 and 3730 xl automated sequencers (Thermo Fisher 
Scientific). Data analysis was performed using SeqScape v2.5 
software (Thermo Fisher Scientific).
The history of atrial fibrillation between the different 
groups of patients was compared using Fisher's exact test. A 
p-value <0.05 was considered to indicate a statistically signifi-
cant difference.
Results
IACP performance. To verify the theoretical coverage of the 
19 genes, all 284 coding exons were analyzed with IAD soft-
ware: 259 (91.2%) were ascribed to theoretical covered exons. 
The NGS analysis of the 73 samples (the training set) showed a 
coverage >20X for each target nucleotide into 253 exons (97.7%) 
(Table I). The remaining exons were classifiable with unsuitable 
coverage and therefore were screened by conventional (Sanger) 
sequencing.
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Figure 1. Depth of coverage and phred-like quality score of 73 samples belonging to training set; the dots and the bars represent the mean values and standard 
deviation, respectively. (A) Distribution of the average depth of coverage of all 452 amplicons (ordered according to the mean coverage, from the least to the 
most represented in the mean depth of coverage per-amplicon); the dashed line indicates the mean coverage (318X) concerning the 452 enriched amplicons of 
all patients. (B) Distribution of the average phred-like quality score related to each base of every amplicon that composes the alignment: the values are included 
between 26,2 and 31,5.
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The mean depth of coverage per amplicon in the 73 samples 
of the training set was 318X and only 21 (4.6%) out of 452 ampli-
cons showed a mean depth <150 reads (Fig. 1A). Six out of the 
73 samples had an average read depth <150X and, among these, 
only 2 samples had an average read depth <100X.
The average phred-like quality score respect at each base 
position of the training set ranged between 26.2 and 31.5, with 
the minimum and maximum value of the standard deviation 
equal to 0.41 and 1.79, respectively (Fig. 1B).
The training set: ‘PGM™ Runs’ evaluation in covered regions 
shows expected and additional mutations. The IACP sequencing 
of the training set confirmed the presence of 72 out of 73 
expected mutations (detection rate of approximately 99%) with 
the known allelic status (Table II). In one sample we missed the 
deletion of the nucleotide at the position 2610 into MYBPC3 that 
is located within a homopolymer of 6 cytosines; in addition, in all 
samples, we observed the false-positive call MYH7:c.136T>C.
Furthermore, following ‘PGM Runs’ evaluation of the 
genes not previously investigated by Sanger sequencing, we 
identified 15 additional mutations (Table II) of which 10 were 
in genes encoding proteins different from (TTms) (4 were in 
genes encoding a protein located in the M-band, 2 were in 
encoding Z-disk constituents genes, 2 were in metabolic genes 
and 2 were in the CAV3 gene). Taking into account the stringent 
criteria established in the ‘Patients and methods’ section, 10 out 
of 15 additional mutations could be ascribed to the category 
‘pathogenic variants’, while the remaining 5 were classified as 
‘likely pathogenic variants’ (Table II).
The training set: the additional mutations are identified 
in HCM subjects with arrhythmias or with pre-excitation 
syndrome. The 15 additional mutations belong to 11 out of 
73 patients (15%) (Table III). In 2 patients, we identified only 
mutations of genes encoding TTm proteins, while in the 
remaining 9 patients, we characterized co-occurring muta-
tions of genes encoding TTm/non-TTm proteins. Three out of 
9 subjects with mutations of genes encoding TTm and non-TTm 
proteins had a personal history characterized by atrial fibril-
lation and non-sustained ventricular tachycardia episodes. 
Additionally, the NGS re-analysis permitted the identification 
of: i) two mutations in the MYL2 gene in one teenager affected 
by hypertrophic obstructive cardiomyopathy that initially, 
following Sanger analysis, was classified as wild-type; ii) the 
missense mutation LAMP2:p.(Val310Ile), already described as 
causative of Danon disease, in a young female affected by HCM 
and with the typical Wolff-Parkinson-White (WPW) electrocar-
diographic pattern (shortened PR interval and delta wave).
The discovery set: PGM ™  Runs evaluat ion for 
19 HCM-related genes in 19 patients. The IACP sequencing 
of 19 DNA samples, and the following PGM Runs evalua-
tion for all genes of the panel, allowed the identification of 
20 mutations in 7 genes (Table IV).
Thirteen mutations were identified in 2 major sarcomeric 
genes, MYBPC3 and MYH7; all 13 mutations were classified 
as ‘pathogenic variants’.
The remaining 7 mutations were identified in the following 
genes: i) MYH6 (2 mutations in thick filament); ii) MYOM1 
(2 mutations in M-band protein); iii) MYOZ2 (one mutation in 
Z-disk constituent); iv) GLA and LAMP2 (one mutation each 
in metabolic genes). Four mutations were classified as ‘patho-
genic variants’ and the remaining 3 were considered as ‘likely 
pathogenic variants’. No false-positive result was identified in 
our discovery set.
The discovery set: mutations in genes encoding non-TTm 
proteins are identified in borderline HCM status and in an 
HCM subject with an extremely complex phenotype. The 
20 mutations were identified in 15 out of 19 patients (Table V). 
A single mutant allele in genes encoding non-TTm proteins 
was identified in 3 patients without a family history of HCM; 
by contrast, the 5 patients that had a family history of HCM 
carried a single mutant allele in genes encoding TTm proteins. 
Two out of 3 patients with only a single mutant allele in genes 
(LAMP2 for female patient, MYOM1) encoding non-TTm 
proteins had a diagnosis of borderline HCM, while the male 
patient with co-occuring mutations in genes encoding TTm 
proteins (MYBPC3 and MYH6) and in the GLA gene showed 
the diagnostic parameter of HCM (LVWT, 19 mm) together 
with a history of atrial fibrillation and multiorgan involvement 
(skin, eyes, ears and thyroid), typical of Fabry disease of male 
patients.
Discussion
Hereditary HCM is historically known as an autosomal 
dominant disease and is associated mainly with mutations in 
the MYBPC3 and MYH7 genes. Over the past years, it has 
become increasingly evident that the same pathogenic muta-
tion, even within the same family, shows a highly variable 
presentation and clinical course in different individuals (18,19). 
Contextually, it has been shown that hereditary HCM can also 
be associated with mutations of genes that do not encode TTm 
proteins (7-12) and, in some patients, more than one pathogenic 
mutation has been identified (22). In consideration of this 
complexity, as well as the possibility of shedding new light on 
the relationship between the genetic and the phenotypic hetero-
geneity, in this study, we designed a target NGS panel, using the 
Ion Torrent PGM system, in order to simultaneously analyze 
a total of 19 genes encoding not only TTm proteins, but also 
other sarcomeric proteins and some non-sarcomeric proteins 
that cause HCM phenocopies (1,3,13).
Our training set allowed us to calibrate the NGS meth-
odology (enrichment, library preparation and bioinformatics 
analysis parameters). With respect to all 284 coding exons, the 
coverage at >20X depth for each target nucleotide (see Patients 
and methods) includes 253 out of 259 exons correctly profiled 
by IAD. This not uniform coverage of our design, as previously 
reported, could be linked to aspects concerning the target gene 
enrichment strategy and at the efficiencies of PCR amplifica-
tion during library preparation (30). It has been reported that 
regions with high a GC content are more difficult to amplify 
and, also, the PGM system has showed a poor coverage within 
AT-rich exonic segments of P. falciparum (31). Additionally, 
in our NGS gene panel, specific genomic regions, such as 
those with a high homology of the MYH6 and MYH7 genes, 
contribute greatly to this inadequate coverage.
With respect to the target NGS study by Gómez et al (32), 
our diagnostic HCM workflow provides the analysis of a larger 
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Table II. Pathogenic or likely pathogenic variants identified by Ion AmpliSeq™ Custom Panel (IACP) sequencing into the 
training set following Runs evaluation for expected and additional mutations of 73 HCM patients.
 Nucleotide Effect on Annotationb Predicted impact Variant
Gene change protein  (HGMD or NCBI) on protein frequency Coverage Q score
ACTC1 c.707C>T p.(Ser236Phe) KU324679 (present study) Pathogenicd 0.48 348 31.81
ACTC1 c.992T>A p.(Ile331Asn) KU324680 (present study) Pathogenicd 0.48 41 29.5
GLA c.514T>C p.(Cys172Arg) CM003746 [DM] Pathogenicc 0.5 1116 31.87
GLA c.1146C>A p.(Cys382*) KU508439 (present study) Pathogenicc 0.32 671 25.31
LAMP2 c.239G>T p.(Gly80Val) KU508440 (present study) Likely pathogenicd 0.49 271 28.6
LAMP2 c.741+1G>T Mis-splicing KU557502 (present study) Pathogenicc 0.5 177 29.23
MYBPC3 c.223G>A p.(Asp75Asn) HM090070 [DM] Pathogenicc 0.46 173 30.15
MYBPC3 c.506-2A>C Mis-splicing CS109051 [DM] Pathogenicc 0.43 191 28.22
MYBPC3 c.557C>T p.(Pro186Leu) CM106110 [DM] Pathogenicc 0.42 45 29.47
MYBPC3 c.649A>G p.(Ser217Gly) CM109108 [DM?] Pathogenicd 0.48 295 26.67
MYBPC3 c.772G>A p.(Glu258Lys) CM981322 [DM] Pathogenicc 0.5 526 30.12
MYBPC3 c.913_914delTT p.(Phe305ProfsX27) CD086092 [DM] Pathogenicc 0.45 410 27.48
MYBPC3 c.977G>A p.(Arg326Gln)  CM020155 [DM?] Likely pathogenicd 0.45 451 27.1
MYBPC3 c.1003C>T p.(Arg335Cys) KU508441 (present study) Pathogenicd 0.5 288 31.23
MYBPC3 c.1090G>A p.(Ala364Thr) CM152770 [DM] Pathogenicc 0.53 232 27.45
MYBPC3 c.1112C>G p.(Pro371Arg) CM102043 [DM] Pathogenicc 0.47 355 28.62
MYBPC3 c.1174delG p.(Ala392Leufs*14) CD086093 [DM] Pathogenicc 0.51 183 26.15
MYBPC3 c.1458-1G>A Mis-splicing rs397515903 (dbSNP) Pathogenicc 0.61 241 29.65
MYBPC3 c.1505G>A p.(Arg502Gln) CM981325 [DM] Pathogenicc 0.43 521 30
MYBPC3 c.1564G>A p.(Ala522Thr) CM057197 [DM] Pathogenicc 0.55 182 29.82
MYBPC3 c.1591G>C p.(Gly531Arg) CM068013 [DM] Pathogenicc 0.57 142 26.98
MYBPC3 c.1615A>G p.(Ile539Val) CM1412245 [DM] Pathogenicc 0.51 215 29.22
MYBPC3 c.1624G>C p.(Glu542Gln) CM971007 [DM] Pathogenicc 0.5 176 32.78
MYBPC3 c.1670dup p.(Ala558Argfs*10) KU508442 (present study) Pathogenicc 0.54 396 29.51
MYBPC3 c.1696T>A p.(Cys566Ser) KU508443 (present study) Pathogenicd 0.35 440 28.53
MYBPC3 c.1790G>A p.(Arg597Gln) CM122972 [DM] Pathogenicc 0.51 635 31.83
MYBPC3 c.2198G>A p.(Arg733His) CM092564 [DM] Pathogenicc 0.44 159 29.97
MYBPC3 c.2258dupT p.(Lys754Glufs*79) CI063699 [DM] Pathogenicc 0.56 167 29.6
MYBPC3 c.2309-2A>G Mis-splicing CS043648 [DM] Pathogenicc 0.48 126 29.91
MYBPC3 c.2311G>A p.(Val771Met) CM056362 [DM] Pathogenicc 0.52 246 31.59
MYBPC3 c.2429G>A p.(Arg810His) CM034546 [DM] Pathogenicc 0.26 528 31.23
MYBPC3 c.2449C>G p.(Arg817Gly) KU508444 (present study) Pathogenicd 0.42 105 22.86
MYBPC3 c.2610delCa p.(Ser871Alafs*8) CD0910615 [DM] Pathogenicc - - -
MYBPC3 c.2618C>T p.(Pro873Leu) CM116747 [DM] Pathogenicc 0.75 106 24
MYBPC3 c.2864_2865 p.(Pro955Argfs*95) CD982813 [DM] Pathogenicc 0.5 599 28.31
 delCT
MYBPC3 c.2906-2A>G Mis-splicing KU508445 (present study) Pathogenicc 0.46 233 22.6
MYBPC3 c.2992C>G p.(Gln998Glu) CM043548 [DM] Pathogenicc 0.48 120 28.12
MYBPC3 c.3065G>C p.(Arg1022Pro) CM058261 [DM?] Pathogenicd 0.42 223 27.13
MYBPC3 c.3103G>A p.(Ala1035Thr) rs552505566 (present study) Likely pathogenicd 0.39 46 31
MYBPC3 c.3192dupC p.(Lys1065Glnfs*12) CI068119 [DM] Pathogenicc 0.51 95 28.26
MYBPC3 c.3331-1G>A Mis-splicing KU508446 (present study) Pathogenicc 0.45 78 30.25
MYBPC3 c.3364A>T p.(Thr1122Ser) KU508447 (present study) Pathogenicd 0.6 102 30.52
MYBPC3 c.3370T>C p.(Cys1124Arg) CM119645 [DM] Pathogenicc 0.55 137 28.65
MYBPC3 c.3551C>A p.(Thr1184Asn) CM086857 [DM] Pathogenicc 0.51 184 29.78
MYBPC3 c.3560T>G p.(Leu1187Arg) CM086863 [DM] Pathogenicc 0.48 198 29.1
MYBPC3 c.3697C>T p.(Gln1233*) CM014069 [DM] Pathogenicc 0.48 422 30.3
MYBPC3 c.3775C>T p.(Gln1259*) KU508448 (present study) Pathogenicc 0.5 263 23.1
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Table II. Continued.
 Nucleotide Effect on Annotationb Predicted impact Variant
Gene change protein  (HGMD or NCBI) on protein frequency Coverage Q score
MYH7 c.676G>A p.(Ala226Thr) KU319883 (present study) Likely pathogenicd 0.54 120 26.77
MYH7 c.1208G>A p.(Arg403Gln) CM900168 [DM] Pathogenicc 0.5 418 31.68
MYH7 c.1549C>A p.(Leu517Met) CM034554 [DM] Pathogenicc 0.49 201 26.95
MYH7 c.1988G>A p.(Arg663His) CM993620 [DM] Pathogenicc 0.49 247 28.56
MYH7 c.2102G>A p.(Gly701Asp) KU508453 (present study) Pathogenicd 0.51 431 32.93
MYH7 c.2804A>T p.(Glu935Val) KU508449 (present study) Pathogenicd 0.62 174 32.51
MYH7 c.2890G>C p.(Val964Leu) CM087588 [DM?] Pathogenicd 0.42 179 27.32
MYH7 c.3113T>C p.(Leu1038Pro) CM095777 [DM] Pathogenicc 0.5 194 28.45
MYH7 c.3133C>T p.(Arg1045Cys) CM086874 [DM] Pathogenicc 0.48 159 27.57
MYH7 c.3236G>A p.(Arg1079Gln) CM102044 [DM] Pathogenicc 0.51 129 31.65
MYH7 c.4040A>G p.(Tyr1347Cys) KU508450 (present study) Pathogenicd 0.5 202 29.54
MYH7 c.4348G>A p.(Asp1450Asn) CM122821 [DM] Pathogenicc 0.41 51 27.85
MYH7 c.4472C>G p.(Ser1491Cys) CM050712 [DM?] Likely pathogenicd 0.52 522 28.63
MYH7 c.4690G>A p.(Glu1564Lys) KU508451 (present study) Likely pathogenicd 0.25 522 28.46
MYH7 c.5287G>A p.(Ala1763Thr) CM1411014 [DM] Pathogenicc 0.49 348 30.56
PRKAG2 c.905G>A p.(Arg302Gln) CM011949 [DM] Pathogenicc 0.51 438 22.13
TNNI3 c.220C>G p.(Arg74Gly) KU508452 (present study) Pathogenicd 0.22 362 26.83
TNNI3 c.439G>C p.(Val147Leu) CM1411021 [DM] Pathogenicc 0.99 538 26.04
TNNI3 c.485G>A p.(Arg162Gln) CM034575 [DM] Pathogenicc 0.57 234 28.55
TNNI3 c.581A>G p.(Asn194Ser) CM1414551 [DM] Pathogenicc 0.56 178 27.41
TNNT2 c.83C>T p.(Ala28Val) CM063210 [DM] pathogenicc 0.52 174 26.89
TNNT2 c.247G>A p.(Glu83Lys) CM034581 [DM] Pathogenicc 0.46 307 32.69
TNNT2 c.275G>A p.(Arg92Gln) CM951218 [DM] Pathogenicc 0.46 897 25.98
TNNT2 c.536C>T p.(Ser179Phe) CM002871 [DM] Pathogenicc 0.5 699 26.38
TNNT2 c.832C>T p.(Arg278Cys) CM951222 [DM] Pathogenicc 0.6 126 29.11
TPM1 c.644C>T p.(Ser215Leu) CM087722 [DM] Pathogenicc 0.46 669 26.13
MYOM1 c.139A>G p.(Ser47Gly) rs202145133 (dbSNP) Likely pathogenicd 0.37 50 25.25
MYOM1 c.1514A>C p.(Glu505Ala) KU508437 (present study) Likely pathogenicd 0.58 68 27.97
MYOM1 c.2087G>A p.(Arg696His) KU508438 (present study) Pathogenicd 0.51 662 31.44
MYOM1 c.2110G>A p.(Glu704Lys) rs149528866 (dbSNP) Likely pathogenicd 0.47 258 27.57
MYH6 c.3883G>C p.(Glu1295Gln) rs34935550 (dbSNP) Pathogenicd 0.46 74 28.3
MYH6 5476_5477del p.(Gly1826Asn) CX103031 [DM] Pathogenicc 0.3 361 23.38
 GGinsAA
MYH6 c.5797-2A>G Mis-splicing KU508454 (present study) Pathogenicc 0.49 424 19.97
MYOZ2 c.36A>C p.(Lys12Asn) KU508455 (present study) Pathogenicd 0.5 350 30.44
LAMP2 c.928G>A p.(Val310Ile) CM057189 [DM] Pathogenicc 0.49 103 31.68
CAV3 c.216C>G p.(Cys72Trp) CM980306 [DM] Pathogenicc 0.31 393 27.2
CAV3 c.233C>T p.(Thr78Met) CM065052 [DM] Pathogenicc 0.49 712 31.89
ANKRD1 c.827C>T p.(Ala276Val) CM095438 [DM?] Likely pathogenicd 0.51 330 30
MYL2 c.206T>C p.(Met69Thr) KU319885 (present study) Pathogenicd 0.46 315 31.78
MYL2 c.401A>C p.(Glu134Ala) CM086879 [DM] Pathogenicc 0.51 438 22.13
GLA c.937G>T p.(Asp313Tyr) CM930335 [DM?] Likely pathogenicd 1 517 25.61
aUndetected mutation after NGS analysis. bReference nucleotide data: starting with CM/CX/CI/CD/CS/HM for variants annotated in HGMD; starting 
with KU/rs for variants annotated in NCBI (GenBank, accession no./dbSNP). cMutations annotated in Human Genome Mutation Database (HGMD, 
http://www.hgmd.org/; release 2015.4) as DM (disease-causing mutations) and nonsense, frameshift, canonical splice site (±2 bp) mutations identified 
in this study (or annotated only in dbSNP) were classified as ‘pathogenic’. dThe missense mutations not annotated in HGMD and those described as 
‘DM of questionable pathological relevance’ (DM?) were classified as i) ‘pathogenic variants’ if the pathogenic impact was predicted by all algorithms; 
ii) ‘likely pathogenic variants’ if the pathogenic impact was predicted by two out of three algorithms. Bold font indicates the additional mutations 
identified only by NGS analysis. NGS, next generation sequencing; HCM, hypertrophic cardiomyopathy.
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number of genes, including some which encode for proteins 
different from myofilaments of the sarcomere and 3 genes 
responsible for the HCM phenocopy. Moreover, through a 
combined strategy with Sanger sequencing, we ensured a 
depth of coverage >20X for each target nucleotide; other 
studies (15,33) have reported a higher coverage depth, but only 
as a general mean coverage.
According to the training set analysis, we observed only 
one false-negative: our non-identified mutation is located 
into a short homopolymer region that, as has already been 
reported (31), represents a DNA motif particularly prone to 
this error, as in these regions, there is not a linear correlation 
of pH between signal-generated and the number of nucleotides 
incorporated; the only false-positive call MYH7:c.136T>C 
was already reported in another study (32) and it is located 
in the first coding exon that had inappropriate coverage and 
hence, was necessarily analyzed by Sanger sequencing.
Our target NGS panel, applied to the training set encom-
passing 73 patients, allowed the identification of 15 additional 
mutations in 11 patients (Table III); these mutations were 
characterized in genes originally not analyzed by Sanger 
sequencing: 10 belong to genes encoding proteins of the sarco-
mere different from (TTms) and, of these, 4 are mutant alleles 
of the MYOM1 gene that have previously been associated with 
HCM in a single study (7). One out of 10 patients, that origi-
nally showed wild-type status after Sanger analysis, carried 
2 pathogenic alleles in the MYL2 gene that could support 
the molecular diagnosis of hereditary HCM, whereas for the 
remaining 10 out of 63 patients, the newly identified mutation 
(that represents the co-occuring mutation together with other 
already described as causative of HCM) could contribute as 
a modifier of the clinical picture in the affected patients of 
each HCM family (3,16,22,33); for example, the WPW elec-
trocardiographic pattern of patient #748 (female), that carries a 
mutant allele in the genes LAMP2 (X-linked) and MYH7, has 
already been documented by Cheng et al (34) in some patients 
with Danon disease and mutation in the LAMP2 gene.
Our target NGS panel, applied to the discovery set, allowed 
the identification of 20 mutations in 15 patients (Table V). If 
the molecular characterization of these patients was performed 
with the older diagnostic workflow, a mutant allele would have 
been identified only in 11 patients, as the analysis of LAMP2 
and GLA genes would have had to be specifically requested 
and the Sanger assay did not include the screening of the 
MYOM1, MYOZ2 and MYH6 genes.
The evaluation of the discovery set, even though it is repre-
sented by only 15 patients with mutations, seems to suggest 
that the presence of only one mutant allele in genes encoding 
non-TTm proteins (LAMP2, MYOM1 and MYOZ2) is asso-
ciated with a milder HCM status: 2 out of 3 patients had a 
diagnosis of borderline HCM and none of these 3 patients had 
a family history of HCM or SCD; at the same time, mutations 
in genes encoding TTm proteins have been identified in all 
patients that had a family history of HCM and in only one 
patient with a diagnosis of borderline HCM. Consistent with 
the findings of larger studies on genotype-phenotype correla-
tions (35,36), although this study did not have this objective, 
we found that patients without myofilament mutations, 
encompassing a female subject with single mutant allele in the 
LAMP2 (X-linked) gene, show a less severe phenotype.
Interestingly, among the 26 patients of which we report the 
clinical data, 4 out of 10 HCM subjects with concomitant muta-
tions in genes encoding TTm and non-TTm proteins have also 
had a history of atrial fibrillation; although, this small sample 
can only suggest a trend, when the arrhythmia was compared 
between this subset of patients and the remaining 16 subjects 
carrying mutations in genes encoding TTm (13 patients) 
or non-TTm proteins (3 patients) only, the distribution was 
significantly different (Fisher's exact test, p<0.05).
Our data suggest that the screening of new genes using the 
NGS methodology increases the number of identified muta-
tions. In particular, the discovery set has allowed us to increase 
the diagnostic yield from 58 to 79%. Additionally, with respect 
to the Sanger sequencing, the genotyping of the discovery 
set with NGS methodology has allowed a reduction in turn-
around-time for HCM of approximately 75%.
Therefore, in our new diagnostic workflow, including the 
screening of genes encoding non-TTm proteins, despite the 
drawback represented by the need to combine targeted NGS 
and Sanger sequencing in order to obtain a depth of coverage 
>20X for each target nucleotide, the use of the Ion PGM system 
has showed the following advantages: i) an important decrease 
in the turn-around-time; ii) an increase in the diagnostic yield; 
iii) the detection of multiple mutations, or single mutant alleles 
in genes encoding non-TTm proteins, that contribute to better 
defining the genetic and phenotypic heterogeneity of HCM: 
mutations in genes encoding only non-TTm proteins seem to 
show a milder HCM status, whereas co-occuring mutations of 
genes encoding TTm and non-TTm proteins could explain the 
wide variability of the HCM phenotype.
Given the complexity of target NGS methodology, and 
as previously suggested by the guidelines of the American 
College of Medical Genetics and Genomics (37), when the 
genetic test is requested for clinical diagnostic purposes, this 
technique should be performed by highly specialized laborato-
ries, i.e., laboratories with ISO9001 certification and possibly 
with the professional accreditation (in Italy SIGU-CERT, 
Italian Society of Human Genetics certification program).
The target NGS methodology, by permitting a more rapid 
analysis of a large number of causative genes, may prove to 
be useful in unveiling the significant genetic heterogeneity of 
this complex disease that, conjugated with the broad pheno-
typic heterogeneity, may improve genetic counselling and the 
clinical management of patients.
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